Breaking News
March 21, 2019 - Allergan Announces FDA Approval of Avycaz (ceftazidime and avibactam) for Pediatric Patients
March 21, 2019 - Mutations in noncoding genes could play big role in regulating cancer, study finds
March 21, 2019 - A medical student’s thoughts on Match Day
March 21, 2019 - Are eggs good or bad for you?
March 21, 2019 - New analysis reveals precision oncology insights for colorectal cancer
March 21, 2019 - Pollutants appear to weaken immune system and increase pathogen virulence
March 21, 2019 - Researchers develop and validate scale for rating severity of mononucleosis
March 21, 2019 - Scientists identify generation of key immune response in mice on introducing solid food
March 21, 2019 - New nanomaterial could restore internal structure of damaged bones
March 21, 2019 - Selective destruction of prostate tumor as effective as complete prostate removal
March 21, 2019 - 2011 to 2015 Saw Increase in Psychiatric ED Visits for Youth
March 21, 2019 - Tapeworm drug targets common vulnerability in tumor cells
March 21, 2019 - Off the beaten path for global health residency
March 21, 2019 - European Parliament’s report calls on EU to develop policies to regulate endocrine-disrupting chemicals
March 21, 2019 - Women with undiagnosed diabetes in pregnancy more likely to experience stillbirths
March 21, 2019 - Fish consumption can help prevent asthma, study reveals
March 21, 2019 - Royal Holloway professors to lead new to research into curing Neurofibromatosis type 1
March 21, 2019 - NSF offers grant to improve treatment approaches for pelvic organ prolapse
March 21, 2019 - Your Apple Watch Might Help Spot a Dangerous Irregular Heartbeat
March 21, 2019 - Research team uncovers critical new clues about what goes awry in autistic brains
March 21, 2019 - From March Madness to medicine with help from mentors
March 21, 2019 - Mental health disorders among young adults may be on the increase
March 21, 2019 - New study examines smarter automatic defibrillator
March 21, 2019 - UC Riverside research shows how natural selection favors cheaters
March 21, 2019 - Mother’s diet during pregnancy can impact lung-specific genes of her offspring
March 21, 2019 - AeroForm Tissue Expanders makes breast reconstruction after mastectomy more comfortable
March 21, 2019 - New project focuses on creating more responsive, intuitive prosthetics
March 21, 2019 - New case study describes adolescent patient with rapid-onset schizophrenia and Bartonella infection
March 21, 2019 - Umass Amherst food scientist honored with 2019 Young Scientist Research Award
March 21, 2019 - Smell of skin could lead to early diagnosis for Parkinson’s
March 21, 2019 - Difference in brain connectivity may explain autism spectrum disorder
March 21, 2019 - Untangling the microbiome — with statistics
March 21, 2019 - Human microbiome metabolites enhance colon injury by enterohemorrhagic E. coli, study shows
March 21, 2019 - Written media can improve citizens’ understanding of palliative care
March 21, 2019 - New research aims to find how asthma symptoms are aggravated
March 21, 2019 - New $9.7 million NIH grant project seeks to improve hearing restoration
March 21, 2019 - Researchers measure brain metabolite levels in people with mild memory problems
March 21, 2019 - FDA approves first drug for treatment of postpartum depression in adult women
March 20, 2019 - Gene editing and designer babies experiments face global moratorium
March 20, 2019 - Major scientific study of wound care dressings wins ‘Best Clinical or Preclinical Research Award’
March 20, 2019 - Biohaven Enrolls First Patient In Phase 3 Generalized Anxiety Disorder (GAD) Trial Of Troriluzole
March 20, 2019 - Big data study identifies drugs that increase risk of psychosis in youth with ADHD
March 20, 2019 - Mystery novel and dream spur key scientific insight into heart defect | News Center
March 20, 2019 - Study measures impact of policies designed to reduce air pollution in two mega-cities
March 20, 2019 - Mild sleep apnea during pregnancy changes sugar levels and may affect infant growth patterns
March 20, 2019 - SSB and Novasep collaborate to develop new membrane chromatography systems
March 20, 2019 - Leaky valve repair improves quality of life in heart failure patients
March 20, 2019 - Diattenuation Imaging offers structural information of difficult to access brain regions
March 20, 2019 - Early sports specialization linked to increased injury rates during athletic career
March 20, 2019 - Study brings clarity about milk intake for children with Duarte galactosemia
March 20, 2019 - Allergan Announces FDA Acceptance of New Drug Application for Ubrogepant for the Acute Treatment of Migraine
March 20, 2019 - Maternal smoking during pregnancy increases risk of ADHD among offspring up to three-fold
March 20, 2019 - Pioneering pediatric kidney transplant surgeon Oscar Salvatierra dies at 83 | News Center
March 20, 2019 - F.D.A. Approves First Drug for Postpartum Depression
March 20, 2019 - TB remains a major public health challenge in the European region
March 20, 2019 - Most pills contain common allergens, warn experts
March 20, 2019 - Researchers discover previously unknown mechanism by which cells can sense oxygen
March 20, 2019 - World’s leading source of data on diagnosis, treatments for aortic dissection
March 20, 2019 - Breast cancer relapse predictor may soon be a reality
March 20, 2019 - Researchers identify origin of chronic pain in humans
March 20, 2019 - Two-drug combinations containing calcium channel blocker significantly lowers BP
March 20, 2019 - King’s scientists to monitor air quality exposure of 250 children
March 20, 2019 - Active substance from plant could turn into a ray of hope against eye tumors
March 20, 2019 - Preventative cardioverter defibrillator implantation is of little benefit to kidney dialysis patients
March 20, 2019 - New method based on neurofeedback may reduce anxiety
March 20, 2019 - Study explores whether alcohol consumption can have an effect on arthritis
March 20, 2019 - Merck to collaborate with GenScript for plasmid and virus manufacturing in China
March 20, 2019 - FDA Approves Zulresso (brexanolone) for the Treatment of Postpartum Depression
March 20, 2019 - Study examines long-term opioid use in patients with severe osteoarthritis
March 20, 2019 - Retired Stanford professor Edward Rubenstein, pioneer in intensive care medicine, dies at 94 | News Center
March 20, 2019 - Aaron Diamond AIDS Research Center to Join Columbia University
March 20, 2019 - Call for halt to human gene editing and designer babies experiments
March 20, 2019 - Study illuminates how hot spots of genetic variation evolved in the human genome
March 20, 2019 - Roundworm study suggests alternatives for treatment of schizophrenia
March 20, 2019 - Sphingotec reports new applications of bio-ADM at 39th ISICEM
March 20, 2019 - Preventing falls through free community-based screenings for older adults
March 20, 2019 - AAOS: Supplement Use Low in Patients With Osteoporosis, Hip Fracture
March 20, 2019 - Does intensive blood pressure control reduce dementia?
March 20, 2019 - Nut consumption could be key to better cognitive health in older people
March 20, 2019 - Drinking hot tea associated with increased risk of esophageal cancer
FGF-18 Drug Builds Knee Cartilage in Osteoarthritis

FGF-18 Drug Builds Knee Cartilage in Osteoarthritis

image_pdfDownload PDFimage_print

Action Points

  • Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.

SAN DIEGO — Intra-articular injections of a protein drug derived from fibroblast growth factor-18 in patients with knee osteoarthritis (OA) led to increases in mean cartilage thickness within the joint after two years, although no significant change in symptom scores was seen, a researcher said here.

At the highest dose of the drug, called sprifermin, mean total MRI-measured cartilage thickness in the knee joint increased by 0.03 mm at the year 2 evaluation, whereas patients receiving placebo injections had a loss of 0.02 mm in cartilage thickness, said Marc Hochberg, MD, of the University of Maryland School of Medicine in Baltimore.

Other radiologic measures of joint structure also showed a significant benefit for sprifermin at the higher dose, Hochberg said at a late-breaking session at the American College of Rheumatology annual meeting. But the same downward trajectory was seen in scores on the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) scale for all treatment groups including placebo.

Hochberg noted that the phase II study is planned to extend for 5 years, and said the investigators still hold out hope that clinical symptoms will improve with sprifermin in these later years. He also pointed out that patients were permitted to take pain medications during the study, which could have masked clinical effects from the drug during this initial portion of the study.

In the trial, approximately 550 patients were randomized to receive placebo or one of four doses of sprifermin, in injections given three times over a week, repeated every 6 months through month 18. Sprifermin dosing groups were 30 mcg per cycle every 12 months; 30 mcg per cycle every 6 months; 100 mcg per cycle every 12 months; or 100 mcg per cycle every 6 months. To maintain blinding, the 12-month sprifermin groups received placebo injections at months 6 and 18.

Median patient age was about 65, and 70% were female. OA was graded at Kellgren-Lawrence level 2 in roughly 70%; the rest were at grade 3. Mean WOMAC score at baseline was about 40.

At the end of year 2, WOMAC scores declined by 18 to 22 points in all groups, with no significant differences or any trends worth noting.

However, the trial technically succeeded because its prespecified primary endpoint was change in total knee joint cartilage thickness, and all secondary endpoints except for WOMAC score were also radiologic assessments of cartilage thickness and joint space width.

On those measures, the two higher sprifermin doses did very well (Results with the 30-mcg doses, whether patients received two or four cycles, did not differ markedly from placebo).

Highly significant differences from the placebo group were seen in the two 100-mcg dosing groups for MRI-measured medial and lateral tibiofemoral cartilage thickness, both overall and in the central subregions of these cartilage compartments. Medial and lateral minimum joint space width, as measured by x-ray, also significantly favored the high-dose sprifermin groups.

The high-dose groups did experience higher rates of acute inflammatory responses: 22% and 23% for those receiving four and two cycles of 100 mcg, respectively, compared with 13.5% for placebo. All of these occurred in the first cycle, Hochberg said, and none led to study dropout. In all other respects, rates of adverse events of various kinds were the same in all groups, he reported.

Sprifermin’s developer, Merck KGaA of Darmstadt, Germany, said it was “highly encouraged” by the study results, but stopped short of promising a phase III trial.

The study was sponsored by Merck KGaA. Co-authors included employees of EMD Serono, a unit of Merck KGaA.

Hochberg disclosed relevant relationships with Bioiberica, Bristol Myers-Squibb, EMD Serono, Galapagos, IBSA, Eli Lilly, Novartis, Pfizer, Plexxikon, Samumed, Theralogix, and TissueGene.

2017-11-09T09:30:00-0500

Tagged with:

About author

Related Articles